DOCSLIB.ORG

Annual Report 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2014 Annual Report 2014 P E R F OR M A NC E INNOVATION ENGAGEMENT Reporting solid results, Roche From prevention to life- More than 80% of employees will propose an increase of the extending medicines, important are proud to work for Roche. dividend for the 28th year pipeline breakthroughs in 2014 Find out what the company is running. Discover how the new included an HPV test for doing to create a great Chairman, Christoph Franz, cervical cancer and survival workplace where people feel plans to build on this strong data of nearly 5 years for a engaged and inspired to do foundation. Roche breast cancer medicine. their best work. 08 52 108 Contents 04 OPENING SECTION 52 INNOVATION 04 Roche in 2014 54 Diverse approaches to R&D 06 Our business priorities 55 Innovative R&D: targeted therapies 56 Leading innovations from our pipeline 65 Innovative approaches for clinical studies 08 LETTERS 66 Reliable supply to patients 67 Health IT: interpreting Big Data 08 Letter from the Chairman 68 Spotlight on HPV testing 12 Board of Directors 72 Value of diagnostic test results 14 Letter from the CEO 74 Building partnerships around the world 18 Corporate Executive Committee 76 Conducting responsible R&D 78 Pharmaceuticals pipeline 20 BUSINESS REVIEW AND MARKET ENVIRONMENT 80 ACCESS TO HEALTHCARE 22 Solid growth in both divisions 82 An enormous global challenge 24 The big picture 83 Improving affordability 25 Focusing on value 86 Increasing availability of innovative products 25 Access to healthcare 87 Strengthening infrastructure 26 Technological advances 88 Increasing awareness and patient support 27 Growth of emerging markets 90 Spotlight on Africa 28 DIAGNOSTICS 94 RESPONSIBLE BUSINESS 30 Good sales growth in 2014 96 Integrity is at the core of everything we do 32 Setting new industry standards with new instruments 97 Increasing transparency 34 Adding value in healthcare 98 Engaging with our stakeholders 34 Diagnostics business model 100 Managing risk and crisis 36 Spotlight on Diagnostics Korea 101 Safeguarding patients 104 Spotlight on mental health 40 PHARMACEUTICALS 108 PEOPLE 42 Solid performance in 2014 44 Key products performing well 110 Engaging and energising our people 45 Significant breakthroughs in 2014 111 Recognising and rewarding employees 47 Making innovation accessible 112 Appreciating everyone’s contribution 48 Spotlight on biomarkers 113 Preparing the workplace of the future 114 Developing the full potential of our leaders 115 Making the most of employee careers 116 Spotlight on professional development 36 48 120 ENVIRONMENT AND COMMUNITY 122 Reducing our environmental footprint 68 124 Occupational and mental health 125 Environmental sustainability 130 Security 131 Pharmaceuticals in the environment 131 Legislation and compliance 132 Remediation management 134 Spotlight on sustainability 138 Making a difference with philanthropy 140 CORPORATE GOVERNANCE AND REMUNERATION REPORT 142 Corporate Governance 90 152 Remuneration Report 168 Report of the Statutory Auditor 116 170 CLOSING SECTION 170 Assurance Report 172 More on the Web 174 Impressum 176 Our purpose statement 104 134 Roche | Roche in 2014 Roche in 2014 ROCHE IS A RESEARCH-BASED HEALTHCARE COMPANY founded in 1896 and headquartered in Basel, Switzerland. We focus on creating truly innovative medicines and diagnostic tests in areas of unmet medical need. Our business model drives our ambition to make a significant difference to patients, reaching as many people in need as possible whilst continuously reinvesting in innovation to develop diagnostic tests and breakthrough treatments. billion Swiss francs Swiss francs 47.5 sales* 14.29 core earnings per share billion Swiss francs 229 market capitalisation 88,509 employees Pharmaceuticals Diagnostics Product pipeline • Esbriet approved in idiopathic pulmonary • New molecular testing systems, the cobas • Anti-PDL1 immunotherapy medicine fibrosis 6800 and cobas 8800, launched in bladder cancer • RoActemra approved in early rheumatoid • HPV test for primary screening of cervical • Lampalizumab in geographic atrophy arthritis cancer approved of the eye • Avastin approved in cervical cancer and • New diagnostic test for syphilis launched • Cobimetinib and Zelboraf in advanced platinum-resistant ovarian cancer • Investment of 450 million Swiss francs melanoma • Gazyvaro approved in chronic lymphocytic over next three years in new diagnostic • ACE910, an innovative bispecific antibody, leukemia manufacturing facility in China in hemophilia A * Unless otherwise stated, all growth rates in this report are at constant exchange rates (CER; average full year 2013). 4 | Roche Annual Report 2014 Roche in 2014 | Roche No. 1 in biotech in oncology in in vitro diagnostics in hospital market Acquisitions Sustainability Group • InterMune in idiopathic pulmonary fibrosis • Dow Jones Sustainability Indices Group • Christoph Franz elected as Chairman • Seragon Pharmaceuticals in hormone leader for sixth year running of the Roche Board of Directors receptor-positive breast cancer • Global access programme to test viral loads • 4 billion Swiss francs of investments • Ariosa Diagnostics in non-invasive pre-natal in people with HIV infections launched announced in state-of-the-art R & D, testing • 5.8 million people treated in 20 years production facilities and infrastructure • Genia Technologies in next-generation gene through the Phelophepa train, a mobile • Increase in dividend proposed for the sequencing health clinic in South Africa 28th consecutive year • IQuum in molecular diagnostics • 71% fully engaged employees • More than 100 new external partnerships Roche Annual Report 2014 | 5 Roche | Our business priorities Our business priorities WE HAVE A CLEAR SET of business priorities aimed at achieving sustainable growth and delivering value to all our stakeholders. Focus on patients Excellence in science Personalised healthcare We focus exclusively on developing innovative We strive to address unmet medical needs We combine our strengths in pharmaceuticals medicines and diagnostic tests that help through excellence in science. Breakthrough and diagnostics to better fit treatments to patients live longer, better lives. Two thirds innovation in science and technology patients. When genetic differences can be of all known diseases are either still not increasingly allow us to understand precisely identified, the efficacy and safety of medicines treated adequately or not treated at all. This what is malfunctioning in the body and can be improved enormously. To this end medical need is an enormous challenge develop drugs to counter the problem. We we have a companion diagnostic strategy for and better diagnostics and medicines can focus on oncology, immunology, infectious every molecule we develop. make a huge difference to the lives of millions diseases, ophthalmology and neuroscience. of patients and their families. However, we remain flexible and follow the science as new insights become available. Performance in 2014 19 million patients on a Roche top 25 selling 66 new molecular entities (NMEs) >350 personalised healthcare collaborations medicine in the pipeline within Roche More than 6 million women tested for HPV 11 pharmaceutical product approvals >15 companion tests in development More than 6.5 billion test strips for blood >170 manuscripts puplished in 41 NMEs with companion diagnostic glucose monitoring sold top-tier journals programmes in pipeline 6 | Roche Annual Report 2014 Our business priorities | Roche Access to healthcare Great workplace Sustainable value We aim to bring our medicines and diagnostic We are committed to constantly maintaining We run our business in a way that is ethical and tests to as many people in need as possible. and strengthening highly attractive aims to create long-term value for shareholders Every healthcare system comes with different workplaces where every person feels valued and all our stakeholders. We want to create challenges and we customise solutions and respected and can grow to his or her value through developing medical solutions and for individual markets. We work with many full potential. Our people make our business. we aim for as many people to benefit from different local partners to reduce barriers to They discover, develop and manufacture our them as possible. We believe that our success accessing healthcare and establish innovative, products and ensure they reach the patients lies in our ability to develop strategies where sustainable ways to bring effective and who need them. We believe that the key to both industry and society benefit in a affordable healthcare to patients. our success lies in our ability to attract, retain sustainable way. and motivate a highly skilled and diverse workforce. Performance in 2014 250,000 women screened for breast cancer 81% of our employees are proud to 11.5% improvement in eco-impact in North Africa through a Roche mobile unit work for Roche 28th consecutive year dividend 1.3 million infants tested for HIV as part 71% fully engaged employees increase proposed of Roche’s AmpliCare programme 48% of total workforce are women 6 times Group leader Dow Jones Global access programme for HIV viral Sustainability Indices load testing launched Roche Annual Report 2014 | 7 Letter to shareholders | Christoph Franz 8 | Roche Annual Report 2014 Christoph Franz | Letter to shareholders Supporting a strategy of lasting success 2014 WAS ANOTHER SUCCESSFUL YEAR FOR ROCHE, with a solid business performance, highly promising medical advances and ground-breaking investments.
Load more

Recommended publications
  • Supporting the Development of a Vision and Strategic Plan for Zhejiang University’S Academic Medical Center
    Supporting the Development of a Vision and Strategic Plan for Zhejiang University’s Academic Medical Center Rafiq Dossani, Peggy G. Chen, Christopher Nelson C O R P O R A T I O N For more information on this publication, visit www.rand.org/t/RR2819 Library of Congress Cataloging-in-Publication Data is available for this publication ISBN: 978-1-9774-0196-0 Published by the RAND Corporation, Santa Monica, Calif. © Copyright 2019 RAND Corporation R® is a registered trademark. Cover image courtesy Zhejiang University Limited Print and Electronic Distribution Rights This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions. The RAND Corporation is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. Support RAND Make a tax-deductible charitable contribution at www.rand.org/giving/contribute www.rand.org Preface Zhejiang University is developing an academic medical center (AMC) in Hangzhou. The Center, which is under construction as of the writing of this report in late 2018, aims to undertake research and training and to provide clinical care in a collaborative and integrated environment.
    [Show full text]
  • Fedora 4 API Extension (API-‐X) Architecture
    Fedora 4 API Extension (API-X) Architecture The Sheridan Libraries at Johns Hopkins University request $120,500 from the Institute of Museum and Library Services (IMLS) to develop a service proxy layer on top of the Fedora 4 software platform that will facilitate the exposure of repository contents and services as linked data web resources. This work was initially inspired by a redesign and refactoring of the Data Conservancy1 software, which was initially prototyped by the Sheridan Libraries and a network of partners through a grant from the National Science Foundation’s (NSF) DataNet program. Following the end of DataNet funding, the Data Conservancy decided to apply the lessons learned and redesign and refactor the entire architecture and software platform. The re-imagined Data Conservancy infrastructure builds upon Fedora 4, a digital object repository platform whose development is led by the nonprofit DuraSpace2 organization. IMLS wisely emphasizes that any national digital platform must leverage and extend existing technology. There is an existing user base of Fedora software for institutional repositories that will grow given the important enhancements and robustness offered by Fedora 4. By providing architecture to deploy repository services as lightweight extensions, institutions that use Fedora 4 for their institutional repository needs would be automatically positioned to extend their platforms for more robust data management. As federal funding agencies respond to the White OSTP memoranda regarding public access to publications and data, it is becoming clear that simply depositing and subsequently downloading data will not be sufficient. The proposed work supports a vision of data management where data are packaged with information graphs that capture and preserve connections to publications and software.3 The direct audience for the proposed API-X work is Fedora 4 software developers and repository managers who support a range of cultural heritage institutions including libraries, museums and archives.
    [Show full text]
  • Samuel James Bader (919) 800 7773 Device Physics, Electrical Engineering, and Scientific Software [email protected]
    Hillsboro OR Samuel James Bader (919) 800 7773 Device Physics, Electrical Engineering, and Scientific Software [email protected] EXPERIENCE SKILLS Intel Components Research,​ Hillsboro, OR —​ Research Eng. Device Modelling July 2020 - present - Sentaurus TCAD - Developing next-generation wide-bandgap technologies. - nextnano - my custom packages X Development (Google X), ​Mountain View, CA —​ Resident [​sambader.net/pynitride​] Summer 2019 - Initiated and developed a confidential early-stage moonshot. Gallium Nitride Devices - HEMT fabrication Jena-Xing Group (Cornell), ​Ithaca, NY — ​Grad. Researcher - R&D/Novel designs August 2015 - May 2020 - p-channel devices - Led a highly-collaborative and interdisciplinary research project. - Executed fabrication and characterization, established a new simulation Software development framework, coordinated experiments with other research groups. - Python 6+ years - Authored multiple papers and conference presentations. - Prior experience with - Organized monthly reviews for corporate funders. many other languages and platforms. Analog Devices, ​Wilmington, MA​ ​— ​Design Intern May 2014 - August 2015, Summer 2016 Leading new initiatives - Developed simulation infrastructure, characterization protocols, and - Proposed, advocated, design recommendations for the process development team. designed, and ran many - Established an internal database and software platform for monitoring projects from scratch and analyzing electrical characterization. - Presented to and took feedback routinely from the EDUCATION corporate stakeholders Cornell University, ​Ithaca, NY — MS, PhD ​Applied Physics Learning on the Job August 2015 - present - Success maneuvering - Performed both independent and collaborative experiments, authored through multiple fields publications and delivered numerous talks and funding reviews. from quantum computing - Supported instruction, mentored students, maintained equipment. to custom software to - Held various managerial roles in Gamma Alpha Scientific Cooperative. wide-gap materials.
    [Show full text]
  • The New Mexican Review, 06-27-1912
    University of New Mexico UNM Digital Repository Santa Fe New Mexican, 1883-1913 New Mexico Historical Newspapers 6-27-1912 The ewN Mexican Review, 06-27-1912 New Mexican Printing Co. Follow this and additional works at: https://digitalrepository.unm.edu/sfnm_news Recommended Citation New Mexican Printing Co.. "The eN w Mexican Review, 06-27-1912." (1912). https://digitalrepository.unm.edu/sfnm_news/8068 This Newspaper is brought to you for free and open access by the New Mexico Historical Newspapers at UNM Digital Repository. It has been accepted for inclusion in Santa Fe New Mexican, 1883-1913 by an authorized administrator of UNM Digital Repository. For more information, please contact [email protected]. NEW MEXK9AN REVIEW NEW MEXICO. THURSDAY. JUNE 27, 1912. MO. 1G VORTV-NINT- H YEAR SANTA FE, FATHER ALLEGES H MEXICO CROP NEW 80N WAS MURDERED. STATISTICS FOR MAY, L STATE BOARD THIRTEEN MILLS Canuto Ares Causes Warrant to Be This State Was the Dryeet In the Issued for Daniel Rolbal Who Union Durlna the Firet Five T OF Killing Was Accident. IS TAX LEW Monthe of Year. 8ayi Las Vegas, N. M., Jjne 20. De- .The Crop Reporter published by the claring that because he had refused Samuel Eldodt Sec-- Department of Agriculture Is Just to Charles Garner Would Have Issues Statement Saying He Superintendent White In Daniel Rolbal permission to pay court Chosen 1 Increase of Per Cent hand for the mouth of June and gives to had shot Thirty Month Will Hands stitutes New Method of hla daughter, the youth retary and Treasurer of the New Mexico crop statistics for the Been Paroled Next Keep and killed Eufraclo Ares, bis son, Over Last Territorial Ou June condi New Board month of May.
    [Show full text]
  • Anal Intercourse: Implications for Rectal Microbicides
    Rectal Microbicide Development: - How Did We Get Here? - What Have we Learned? Craig W. Hendrix, MD Wellcome Professor & Director, Division of Clinical Pharmacology, Johns Hopkins University Disclosures ViiV/GSK: Clinical research contract managed through JHU Gates Foundation: Clinical trial simulation project contract managed through JHU NIH/DAIDS: clinical research funding managed through JHU Objectives Behavioral Understanding What have we learned about relevant behavior & desired product attributes? Method Development What new tools were needed to ask essential questions? Product Development How do drugs and formulations stack up against desired product attributes? Behavioral Understanding Behavioral & Preference Questions Quantifying sexual behavior Sexual practices Lubricants Rectal douche Inform user desires & method development (contextually appropriate) Applicator preferences Most studies used vaginal applicator Project gel – directly compared vaginal applicator & rectal specific applicator Volume acceptability Gel volume escalation to 50 mL Example: Douche Behaviorally-Congruent Carballo-Dieguez A, et al. The use of rectal douches among HIV- uninfected and infected men who have unprotected receptive anal intercourse: implications for rectal microbicides. AIDS Behav 2008;12:860-866. Carballo-Dieguez A, e al. Why rectal douches may be acceptable rectal-microbicide delivery vehicles for men who have sex with men. Sex Trans Dis 2009;36(11) Galea JT, et al. Rectal douching and implications for rectal microbicides among populations vulnerable to HIV in South America: a qualitative study. Sex Transm Infect 2013;0:1-3. Javanbakht M, et al. Prevalence and types of rectal douches used for anal intercourse: results from an international survey. BMC Infectious Diseases 2014;14:95. [FIGURE] Noor SW & Rosser BRS. Enema use among men who have sex with men: A behavioral epidemiologic study with implications for HIV/STI prevention.
    [Show full text]
  • Final Results
    For immediate release 20 March 2019 Frontier Smart Technologies Group Ltd (‘Frontier’ or the ‘Group’) Final Results “FY 2018: a year of transition – with significantly improved EBITDA performance in H2” Frontier (AIM: FST), a pioneer in technologies for Digital Radio and Smart IoT devices, announces its final results for the year ended 31 December 2018 (‘FY 2018’ or the ‘Period’). Financial Highlights • Revenues: US$41.8 million (FY 2017: US$53.0 million), with stronger second half revenues of US$24.8 million • Adjusted EBITDA1: US$1.4 million (FY 2017: US$2.5 million) • R&D expenditure: US$7.5 million expensed (FY 2017: US$8.5 million) • Trading EBITDA2: US$0.8 million (FY 2017 US$2.5 million), with the first half loss of US$(2.1) million reversed in the second half (H2: US$2.9 million) • As of 31 December 2018, the Group’s gross cash balance was US$3.8 million; net debt was US$2.5 million Operational highlights Digital Radio • Continued market leadership in consumer DAB; market volumes stabilising post- completion of Norwegian FM switch-off • New Smart Radio solution due for release in H1 2019 Smart IoT3 • The Group’s multi-ecosystem voice-enabled software is largely complete and R&D expenditure has been reduced • First non-audio Smart IoT design win secured (early 2019) • Licensing team created to address opportunities in Smart IoT; collaboration with NXP Semiconductors established to support Licensing opportunities • First Licensing revenues secured (early 2019) Outlook for FY 2019 • In FY 2019, the Board expects an improvement in Trading EBITDA as the Group maintains its position in Digital Radio and establishes a presence in software licensing for Smart IoT.
    [Show full text]
  • Minutes of a Special Joint City Council and Planning
    MINUTES OF A SPECIAL JOINT CITY COUNCIL AND PLANNING COMMISSION MEETING This meeting was held electronically, via Zoom, due to the COVID-19 gathering restrictions Wednesday, April 1, 2020 at 6:01 PM Present Absent CITY COUNCIL Mayor Julie Fullmer Councilmember John Earnest Councilmember Tyce Flake Councilmember Chris Judd Councilmember Cristy Welsh PLANNING COMMISSION Chair Anthony Jenkins Vice-Chair Jeff Knighton Commissioner Tim Blackburn Commissioner Bryce Brady Commissioner Shan Sullivan Alternate Commissioner Jessica Welch Alternate Commissioner Amber Rasmussen Staff Present: City Manager Jacob McHargue, Public Works Director/City Engineer Don Overson, Assistant City Engineer Chris Wilson, City Attorney David Church, Sergeant Holden Rockwell with the Utah County Sheriff’s Office, Community Development Director Morgan Brim, City Planner Elizabeth Hart, Water/Parks Manager Sullivan Love, City Recorder Pamela Spencer Others Speaking: Resident David Lauret; Ethan Moon with Swig; Steve Hutchings with X Development; Real Estate Agents Truett Chamberlain and Andy Flamm representing the buyer and seller of the Geneva Nitrogen property; Jeff Speck with Jeff Speck LLC; Ryan Hales with Hales Engineering; Reid Ewing with the University of Utah; Pete Evans and Bronson Tatton with Flagship Homes and Anderson Geneva 6:01 PM REGULAR SESSION 1. CALL TO ORDER Mayor Fullmer opened the meeting at 6:01 PM. She gave the invocation. Roll call went as follows: Mayor Fullmer, Councilmembers Earnest, Flake, Judd, and Welsh were present. Planning Commissioner Chair Jenkins, and Planning Commissioners Knighton, Blackburn, Brady, and Sullivan were present. Other Planning Commissioners present were: Tay Gudmundson and Amber Rasmussen. Page 1 of 17 April 1, 2020 Joint Special City Council and Planning Commission Meeting Minutes A video recording of the meeting is available on the Vineyard website and the Vineyard YouTube channel.
    [Show full text]
  • Viper FTP Summary
    FOR IMMEDIATE RELEASE Naarak Studio Introducing New App - Viper FTP Summary: Naarak-Studio, a Mac OS X development team is introducing its new application Viper FTP, the practical and reliable Mac FTP client. The app can be installed on all computers according to the user’s preferences absolutely free. May 13, 2015: Naarak-Studio is presenting its new app Viper FTP for MAC users. The application is a helpful and commanding file manager for Mac OS X along with a remarkable user interface that makes it easy to apply. Speaking to the media, a spokesperson from the Naarak-Studio stated, “Yes, we are presenting our new application Viper FTP - Mac FTP client. We are a team of highly trained and experienced professionals developing pioneering software solutions for Mac OS X. We use the most recent techniques with determination, flexibility and alertness to assist users in accomplishing their objectives with utmost productivity.” He further added, “Naarak Studio assures clients with 100 percent customer satisfaction by providing perfect and practical software products. We aim to be the most preferred name when it comes to developing and offering hi-tech software solutions.” Viper FTP helps in local and remote file management (FTP, SFTP, WebDav, Amazon S3, and YouTube-upload). The application allows users to manage everything including Last connections, Bonjour, Bookmarks and Favourites at one place. One can also convert remote files and folders into HTTP/HTTPS address with an immediate email option. They can check the record of file operations (what, when, where with a server reply) and search, view and edit files straight on a remote server.
    [Show full text]
  • Innovation Labs: Driving the Future of Industry Evolution Analyst Spotlight
    Innovation Labs: Driving the Future of Industry Evolution Analyst Spotlight A Report by Frost & Sullivan April 2019 INNOVATION IN THE DIGITAL AGE % 60of companies state that innovation will be critical to their success over the next 5 years Source: Frost & Sullivan, VIG’s State of Innovation Survey, Oct 2017 N = 282 Innovation has become the most talked-about growth The digital era is revolutionising the way products and strategy at the CEO’s table. Amid new challenges and services are consumed and elevating the importance of transformation in a rapidly digitalising environment, customer experience innovation. The emergence of organisations are increasingly recognising the need to new-age technologies such as cloud, analytics, social invest in innovation to survive and sustain growth. media, automation, IoT sensors/connected devices, cognitive artificial intelligence, and proliferation of startups across all sectors also underscore the need for innovation-led growth. Why Enterprises are Investing in Innovation Changing customer expectations as they get used Proliferation of digital to new/enhanced products startups and ease of market every 3–6 months and tire entry, resulting in new entrants easily of existing products in stealing market share from the market incumbents in a short time Increasing shareholder Easier access to technological value as innovation becomes advancements as the key driver for revenue growth underlying hardware, software, and competitive advantage and services become cheaper and more widely available 2 Innovation Labs: Driving the Future of Industry Evolution Digital transformation, competitive complexities, and changing customer demands are fostering need for a holistic approach to innovation. As a result, innovation has moved up the CEO agenda as a key driver for sustainable growth and competitive advantage.
    [Show full text]
  • Apple Design Awards Live Coverage - the Unofficial Apple Weblog (TUAW) 14.08.2006 20:41 Uhr
    Apple Design Awards Live Coverage - The Unofficial Apple Weblog (TUAW) 14.08.2006 20:41 Uhr Last Name Linden? SecondLifeInsider.com | Add to My AOL, MyYahoo, Google, Bloglines Mac Data Recovery Program Mac & Smartphone Sync Mac Software Development Recovers Mac OS 9 & X Drives Free Demo, Finally, sync Entourage, iCal, Now Outsource your Mac OS X development Fast Easy Data Recovery Contact/UTD, & more to your phone. turnaround, professional work! www.stellarinfo.com www.pocketmac.net www.mercdev.com Ads by Google Ads by Google Apple Macintosh Mac Cocoa Developer OS X Developer Search Add to: My AOL, MyYahoo, Google, Bloglines USB Phones From Ipevo Macintosh Macintosh Macintosh Mac OSX compatible USB Phone Spitzen-Angebote zu Macintosh. Supergünstig: Macintosh Hier Hier findest du dein Lieblingsspiel Fast & Reliable Shipping Macintosh hier! suchen, vergleichen & kaufen! garantiert ohne Spam und Dialer! Worldwide Ads by Google Apple Design Awards Live Coverage Posted Aug 8th 2006 10:57PM by Dan Lurie Filed under: WWDC We join the awards ceremony already in progress: Student Awards: Runner-Up - PhotoPresenter Winner - LineForm Best User Experience: Runner-Up - Bionix FotoMagico Winner - iSale Best Widget: Ads by Google Sponsored Links Runner-Up - WeatherBug Local Weather Joanna Dark returns in Perfect Dark Zero. Winner - iClip lite Macintosh Jump In. Große Produktauswahl. Best OS X Graphics: Top-Anbieter. Jetzt Ready to buy an iPod or an iPod shuffle? suchen, vergleichen, Save time and money. Compare prices and Runner-Up - Unity ordern! store
    [Show full text]
  • Rules and Tools for Cataloging Internet Resources
    Cataloging for the 21st Century □ Course 1 Rules and Tools for Cataloging Internet Resources Trainee Manual Prepared by Steven J. Miller University of Wisconsin-Milwaukee Libraries For The Library of Congress And the Association for Library Collections & Technical Services Library of Congress □ Cataloger's Learning Workshop Washington, DCF FebruaryFFebruary 2008 2008 (1) Instructor Manual -- (2) Trainee Manual ISBN 0-8444-1126-4 (Instructor Manual) ISBN 0-8444-1127-2 (Trainee Manual) Version 2, February 15, 2008 ((S(Sessionesion 2,2 ...........................................................................................................................................was revised by Becky Culbertson, George Prager, Holly Tomren, and Sarah Wallbank ........................................... .............................. February 15, 2008 Version 2, February 15, 2008 in June 2010.) TABLE OF CONTENTS Foreword Course Introduction and Background Session 1. Introduction to Cataloging Internet Resources Examples & Exercises MARC Coding Guide for Exercises Session 2. Cataloging Online Monographs Examples & Exercises Session 3. Cataloging Online Serials Examples & Exercises Session 4. Online Versions, Multiple Content Providers, and Linking Relationships Examples & Exercises Session 5. Cataloging Online Integrating Resources Examples & Exercises Session 6. Updating Online Integrating Resource Records for Changes Exercises Session 7. Machine-Assisted Generation of Cataloging Examples Review and Conclusion Selected Bibliography Glossary Session
    [Show full text]
  • General Corporation Tax (GCT)
    CITY OF NEW YORK DEPARTMENT OF FINANCE 1998 - STOCK ALLOCATION BELOW 100 PERCENT REPORT NAME ISSUERS ALLOCATION PERCENT NAME ISSUERS ALLOCATION PERCENT #78 GIAC LEASING CORPORATION 1.33 A F FIRE PROTECTION CO INC 13.54 "K" LINE AIR SERVICE (U.S.A.) 23.80 A F LEWIS & CO OF NEW YORK 23.20 A B DISTRIBUTORS INC 92.94 A F SUPPLY CORP 82.38 A L SHET METAL FABRICATIONS 69.80 A FEIBUSCH CORP 83.30 A & B AGENCY 25.00 A FINE GAUGE INC 59.27 A & C MECHANICAL INC LONG IS 0.44 A FOSTER HIGGINS INC 16.05 A & D ENTERPRISES, INC 75.45 A G EDWARDS SONS INC 1.45 A & D MECHANICAL INC 65.57 A G H TRIMSOURCE INC 76.57 A & E BUSINESS ADVISORS INC 67.80 A G INTERNATIONAL INC 17.20 A & E DENTAL STUDIO INC 89.20 A G INTERTAINMENT 7.67 A & E MANAGEMENT SYST 2.00 A H ENGINEERS PC 97.22 A & F INSTALLATIONS INC 10.19 A H HARRIS SONS INC 0.17 A & J FIXTURES INC 10.20 A H SCHREIBER CO INC 24.04 A & J FIXTURES, INC. 5.81 A H SPORTSWEAR CO INC 69.19 A & J HEATING & AIR CONDITIONISERVICE 62.50 A H VIDEO SALES REPRESENTIVE 59.56 A & M BILLING CONSULTANTS INC 17.30 A HARTRODT VIA INC 63.60 A & M BRONX BAKING INC 24.95 A HELLER METALS CO INC 90.88 A & N DELIVERY SERVICE, INC. 10.09 A I & ASSOCIATES INC 5.08 A & R DEVELOPMENT INC 45.42 A I PROFESSIONAL CLEANING 88.00 A & R RECYCLING INC.
    [Show full text]